Brief: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206

BioInvent International AB

05/03/2024 12:06

March 5 (Reuters) - BioInvent International AB
 BINV.ST :
    * CASI PHARMACEUTICALS REPORT POSITIVE INTERIM PHASE 1 DATA
FOR
BI-1206 IN THE TREATMENT OF RELAPSED/REFRACTORY INDOLENT
NON-HODGKIN'S LYMPHOMA IN CHINA
    * CASI PHARMACEUTICALS INC - LOOK FORWARD TO REPORTING DATA
OF
BI-1206 FROM ADDITIONAL STUDIES IN FIRST HALF OF 2024
    * CASI PHARMACEUTICALS INC: PHASE 1 DOSE-ESCALATION OF
BI-1206
STUDY SHOWED IMPRESSIVE SIGNS OF CLINICAL EFFICACY
    * CASI PHARMACEUTICALS INC: BI-1206 PRELIMINARY RESULTS
DEMONSTRATED A MANAGEABLE SAFETY PROFILE ACROSS ALL PATIENTS

Source text for Eikon:  ID:nPn9J0pDwa 
Further company coverage:  BINV.ST 

 ((Reuters.Briefs@thomsonreuters.com;))